A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants
NCT07776782
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
A Phase 1, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MT-201 Administered with Concomitant Infliximab in Healthy Participants
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Healthy Volunteer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 19 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Mirador Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- August 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Mirador Clinical Department · San Diego, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.